Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Vir Biotechnology, Inc. | Director | Common Stock | 23.8K | $225K | $9.46 | May 30, 2024 | Direct |
Vir Biotechnology, Inc. | Director | Common Stock | 10K | $94.6K | $9.46 | May 30, 2024 | By Sigal Family Investments, LLC |
Vir Biotechnology, Inc. | Director | Stock Option (Right to Buy) | 16K | $24.5K | $1.53 | May 30, 2024 | Direct |
Adaptimmune Therapeutics PLC | Director | Option to purchase Ordinary Shares | 933K | Jul 3, 2023 | Direct | ||
ALNYLAM PHARMACEUTICALS, INC. | Director | Stock Option (right to buy) | 5.23K | May 16, 2024 | Direct | ||
Surface Oncology, Inc. | Director | Common Stock | 0 | $0.94 | Sep 8, 2023 | Indirect | |
Surface Oncology, Inc. | Director | Stock Option (Right to Buy) | 0 | Sep 8, 2023 | Direct |